T-Cell Therapy for Lymphoma Using Nonengineered Multiantigen-Targeted T Cells Is Safe and Produces Durable Clinical Effects.
Spyridoula VasileiouPremal D LullaIfigeneia TzannouAyumi WatanabeManik KuvalekarWendy L CallejasMrinalini BilgiNicholas WangMengfen J WuRammurti KambleCarlos Almeida RamosRayne H RouceZihua ZengAdrian P GeeBambi J GrilleyJuan F VeraCatherine M BollardMalcolm K BrennerHelen E HeslopCliona M RooneyAnn M LeenGeorge CarrumPublished in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2021)
T cells targeting five TAAs and administered at doses of up to two infusions of 2 × 107 cells/m2 are well-tolerated by patients with lymphoma both as adjuvant and to treat chemorefractory lymphoma. Preliminary indicators of antilymphoma activity were seen in the chemorefractory cohort across both antigen- and dose-escalation phases.